GSK is still trailing in the wake of Anglo-Swedish rival AstraZeneca, which rapidly developed a successful jab alongside Oxford University despite having little prior experience in vaccine development.
“The advance to Phase 3 study follows positive interim Phase 1/2 data which showed that all participants who received the adjuvanted vaccine candidate developed strong neutralising antibody responses,” the pair said Tuesday.
“While many countries have made good progress with vaccination, there remains a need for accessible and affordable COVID-19 vaccines to ensure equitable access and to protect people across the world,” said GSK chief global health officer Thomas Breuer.
Results from the Phase 3 trial, which will enrol 4,000 participants from various nations, are expected in the first half of next year. This will be the first Phase 3 study to compare outcomes of two different Covid-19 vaccine candidates.
Glaxo is also working with French pharmaceutical giant Sanofi NSE 2.24 % on final Phase 3 tests of a different Covid vaccine, which they hope to launch by the end of this year.
Phase 2 trials of that jab have already showed a strong immune response after a single shot in participants who had previously contracted the coronavirus.
GSK is also working on another two separate vaccine projects, one with Canada’s Medicago and another with Germany’s CureVac.